Benzinga
01 Jun 2026, 02:43 UTC · 3h ago
Source · https://www.benzinga.com/news/health-care/26/05/52895326/revolution-medicines-pancreatic-cancer-pill-doubles-survival-stock-highs
Read source
Search tags
Story key points
3 claims · impact-rated
Revolution Medicines' experimental pill, daraxonrasib, reduced the risk of death by 60% and more than doubled median overall survival compared to chemotherapy in metastatic pancreatic cancer patients with KRAS mutations. — Exceptional clinical trial results for a deadly cancer type typically lead to significant valuation increases and high probability of regulatory approval.
+0.90The FDA approved an expanded access program for daraxonrasib, allowing eligible patients to receive the drug before formal regulatory approval. — FDA expanded access indicates a high level of confidence in the drug's safety and efficacy, serving as a positive regulatory signal.
+0.50The clinical study for daraxonrasib met its progression-free survival endpoint, demonstrating substantially longer disease control than standard treatment. — Meeting primary endpoints strengthens the clinical case for the drug, supporting future commercial viability.
+0.40Continue reading
6 related stories
Ticker attribution
Model heads
The company announced breakthrough trial data showing its pancreatic cancer pill doubled survival and significantly reduced the risk of death.
No ticker relationship head found.
Impact vectors
6 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
PRNewsWire
6h ago
